Immunome partners with AbbVie for up to 10 novel oncology targets; $30M upfront

Immunome Inc.

Immunome grants AbbVie options to purchase up to 10 novel antibody-target pairs from three tumor types.
Upfront payment of $30M; potential platform access payments up to $70M based on research continuations.
Development and first commercial sale milestones up to $120M per target; sales milestones and tiered royalties low single digits.
Research term at least 66 months; exclusive to AbbVie for selected tumor types during term.
Collaboration leverages Immunome's Discovery Engine; Immunome retains platform technology rights.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Immunome Inc. entered into Collaboration Agreement with AbbVie Global Enterprises Ltd. valued at $30 million (effective 2023-01-04).

Action: entry
Agreement: collaboration
Counterparty: AbbVie Global Enterprises Ltd.
Value: $30 million
Effective: 2023-01-04

Exact text from the filing

On January 4, 2023, Immunome, Inc. (the “ Company ”) entered into a collaboration and option agreement (“ Collaboration Agreement ”) with AbbVie Global Enterprises Ltd. (“ AbbVie ”),

View on SEC.gov

Browse all material agreements →

Immunome Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-001705

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.